美團買藥啟動「重點疫情藥品保供」專項扶持
內媒報道,為緩解各地實地藥店面臨的備貨壓力,同時平抑重點藥品的價格,美團(03690.HK)旗下美團買藥表示,將面向上線經營的20萬家實體藥店啟動「重點疫情藥品保供給」專項扶持,於2022年12月15日至2023年1月13日期間,實體藥店商家通過美團買藥平台銷售「重點疫情藥品保供給」清單中的藥品,將獲得專屬補貼資金,補貼金將在對應藥品銷售訂單完成後三日打到商家賬戶。
據悉,「重點疫情藥品保供給」清單中包括治療新冠治療需要的清熱解毒、感冒、發熱、咽痛、咳嗽五大類15種藥品,例如「感冒靈顆粒」、「復方烷胺片」、「連花清瘟膠囊」、「布洛芬」、「蒲地藍消炎口服液」及「氨溴特羅口服液」等權威機構推薦的新冠常用藥和兒童用藥均在清單中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.